A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer

Blood

Volumn 119, Issue 25, 2012, Pages 6043-6051

  Elvington, Michelle ^a   Huang, Yuxiang ^a   Morgan, B Paul ^b   Qiao, Fei ^a   Van Rooijen, Nico ^c   Atkinson, Carl ^a   Tomlinson, Stephen ^a,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD16 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; CR2FC PROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; CYTOLYSIS; CYTOTOXICITY; GENE CONSTRUCT; HUMORAL IMMUNITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MACROPHAGE; MELANOMA; METASTASIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN TARGETING;

EID: 84862733696     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-383232     Document Type: Article

References (44)

1. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 2004;25(3):158-164. (Pubitemid 38249490)
2. Perlmann H, Perlmann P, Schreiber RD, Muller-Eberhard HJ. Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors: enhancement of antibody-mediated cellular cytotoxicity. J Exp Med. 1981;153(6):1592-1603. (Pubitemid 11067642)
3. Dunkelberger JR, Song WC. Role and mechanism of action of complement in regulating T-cell immunity. Mol Immunol. 2010;47(13):2176-2186.
4. Heeger PS, Kemper C. Novel roles of complement in T effector cell regulation. Immunobiology. 2012;217(2):216-224.
5. Kemper C, Atkinson JP. T-cell regulation: with complements from innate immunity. Nat Rev Immunol. 2007;7(1):9-18. (Pubitemid 46020823)
6. Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R. Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol. 2007;178(9):5991-5998. (Pubitemid 46674397)
7. Junnikkala S, Hakulinen J, Jarva H, et al. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer. 2002;87(10):1119-1127. (Pubitemid 35418107)
8. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol. 1996;149(1):129-142. (Pubitemid 26230985)
9. Li L, Spendlove I, Morgan J, Durrant LG. CD55 is over-expressed in the tumour environment. Br J Cancer. 2001;84(1):80-86. (Pubitemid 32102508)
10. Varela JC, Atkinson C, Woolson R, Keane TE, Tomlinson S. Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int J Cancer. 2008;123(6):1357-1363.
11. Cheung NK, Walter EI, Smith-Mensah WH, et al. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest. 1988;81(4):1122-1128.
12. Ohta R, Kondor N, Dohi N, et al. Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo. J Immunol. 2004;173(1):205-213. (Pubitemid 38797343)
13. Gelderman KA, Kuppen PJ, Okada N, Fleuren GJ, Gorter A. Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model. Cancer Res. 2004;64(12):4366-4372. (Pubitemid 38802445)
14. Imai M, Ohta R, Okada N, Tomlinson S. Inhibition of a complement regulator in vivo enhances antibody therapy in a model of mammary adenocarcinoma. Int J Cancer. 2004;110(6):875-881. (Pubitemid 38758514)
15. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol. 2004;5(10):981-986. (Pubitemid 41057714)
16. Varela JC, Imai M, Atkinson C, et al. Modulation of protective T-cell immunity by complement inhibitor expression on tumor cells. Cancer Res. 2008;68(16):6734-6742.
17. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317-327.
18. Imai M, Ohta R, Varela JC, Song H, Tomlinson S. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Cancer Res. 2007;67(19):9535-9541. (Pubitemid 47535944)
19. Kinoshita T, Thyphronitis G, Tsokos GC, et al. Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor. Int Immunol. 1990;2(7):651-659. (Pubitemid 20232464)
20. Song H, He C, Knaak C, et al. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest. 2003;111(12):1875-1885. (Pubitemid 38057732)
21. Orren A, Hayakawa J, Johnson JE, Nash HR, Hobart MJ. Allotypes of mouse complement component C6 in inbred strains and some wild populations. Immunogenetics. 1988;28(3):153-157.
22. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med. 1995;182(5):1609-1614.
23. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174(1):83-93.
24. Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res. 1998;58(13):2844-2849. (Pubitemid 28311917)
25. Imai M, Landen C, Ohta R, Cheung NK, Tomlinson S. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res. 2005;65(22):10562-10568. (Pubitemid 41743751)
26. Ong GL, Mattes MJ. Mouse strains with typical mammalian levels of complement activity. J Immunol Methods. 1989;125(1):147-158. (Pubitemid 20018017)
27. Osmers I, Szalai AJ, Tenner AJ, Barnum SR. Complement in BuB/BnJ mice revisited: serum C3 levels and complement opsonic activity are not elevated. Mol Immunol. 2006;43(10):1722-1725.
28. Hara T, Kojima A, Fukuda H, et al. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Br J Haematol. 1992;82(2):368-373.
29. Sokoloff MH, Nardin A, Solga MD, et al. Targeting of cancer cells with monoclonal antibodies specific for C3b(i). Cancer Immunol Immunother. 2000;49(10):551-562.
30. Catellani S, Pierri I, Gobbi M, Poggi A, Zocchi MR. Imatinib treatment induces CD5+B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. PLoS One. 2011;6(4):e18925.
31. Kennedy AD, Solga MD, Schuman TA, et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood. 2003;101(3):1071-1079. (Pubitemid 36139381)
32. Peng W, Zhang X, Mohamed N, et al. A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation. Cancer Immunol Immunother. 2005;54(12):1172-1179. (Pubitemid 41416949)
33. Seya T, Nagasawa S. Limited proteolysis of complement protein C3b by regulatory enzyme C3b inactivator: isolation and characterization of a biologically active fragment, C3d,g. J Biochem. 1985;97(1):373-382. (Pubitemid 15158971)
34. Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the anti-tumor immune response by complement. Nat Immunol. 2008;9(11):1225-1235.
35. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A. 1998;95(2):652-656. (Pubitemid 28083798)
36. Takechi Y, Hara I, Naftzger C, Xu Y, Houghton AN.A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res. 1996;2(11):1837-1842. (Pubitemid 26384150)
37. Schreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes: II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest. 1972;51(3):583-589.
38. Atkinson JP, Frank MM. The effect of Bacillus Calmette-Guerin-induced macrophage activation on the in vivo clearance of sensitized erythrocytes. J Clin Invest. 1974;53(6):1742-1749.
39. Brown EJ, Hosea SW, Frank MM. The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. Rev Infect Dis. 1983;5(Suppl 4):S797-S805.
40. Zent CS, Chen JB, Kurten RC, et al. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res. 2004;28(5):495-507. (Pubitemid 38453062)
41. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non- Hodgkin lymphomas. Blood. 2004;104(6):1793-1800. (Pubitemid 39202289)
42. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749-1755.
43. Abes R, Gelize E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood. 2010;116(6):926-934.
44. Boross P, Jansen JH, de Haij S, et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica. 2011;96(12):1822-1830.